203 results on '"Foca, F."'
Search Results
2. Therapy with 177Lu-PSMA-617 in advanced mCRPC patients: Results of the phase 2 prospective trial IRST-185.03 (EUDRACT: 2016-002732-32)
- Author
-
Marini, I., primary, Sansovini, M., additional, Paganelli, G., additional, Grassi, I., additional, Matteucci, F., additional, Nicolini, S., additional, De Giorgi, U., additional, Giunta, E.F., additional, Foca, F., additional, Monti, M., additional, Celli, M., additional, Caroli, P., additional, Di Iorio, V., additional, Sarnelli, A., additional, Lolli, C., additional, Schepisi, G., additional, Brighi, N., additional, and Severi, S., additional
- Published
- 2023
- Full Text
- View/download PDF
3. Malignant Pleural Mesothelioma and Radiotherapy: Lung Toxicity Results of an Interim Analysis in Prospective Pilot Trial
- Author
-
Parisi, E., primary, Arpa, D., additional, Ghigi, G., additional, Fabbri, L., additional, FOCA, F., additional, Tontini, L., additional, Neri, E., additional, Pieri, M., additional, Cima, S., additional, Micheletti, S., additional, Abousiam, R.N., additional, Burgio, M.A., additional, Tonelli, V., additional, Belli, M.L., additional, Luzzi, L., additional, and Romeo, A., additional
- Published
- 2023
- Full Text
- View/download PDF
4. Hyperbaric Oxygen Therapy plus Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma
- Author
-
Arpa, D., primary, Parisi, E., additional, Ghigi, G., additional, FOCA, F., additional, Fabbri, L., additional, Cenni, P., additional, Longobardi, P., additional, Celli, M., additional, Tontini, L., additional, Neri, E., additional, Pieri, M., additional, Cima, S., additional, Micheletti, S., additional, Abousiam, R.N., additional, Tonelli, V., additional, Amadori, E., additional, Tesei, A., additional, and Romeo, A., additional
- Published
- 2023
- Full Text
- View/download PDF
5. Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial
- Author
-
Nanni, O., Amadori, D., De Censi, A., Rocca, A., Freschi, A., Bologna, A., Gianni, L., Rosetti, F., Amaducci, L., Cavanna, L., Foca, F., Sarti, S., Serra, P., Valmorri, L., Bruzzi, P., Corradengo, D., Gennari, A., and MYME investigators
- Published
- 2019
- Full Text
- View/download PDF
6. Radiotherapy and palliative care outpatient clinic: a new healthcare integrated model in Italy
- Author
-
Rossi R., Foca F., Tontini L., Pieri M., Micheletti S., Nanni O., Altini M., Massa I., Pallotti M. C., Ricci M., Romeo A., Muolo M. G., Galeotti G., Valenti V., Tenti M. V., Donati C. M., Pensieri M. V., Morganti A. G., Maltoni M., Rossi R., Foca F., Tontini L., Pieri M., Micheletti S., Nanni O., Altini M., Massa I., Pallotti M.C., Ricci M., Romeo A., Muolo M.G., Galeotti G., Valenti V., Tenti M.V., Donati C.M., Pensieri M.V., Morganti A.G., and Maltoni M.
- Subjects
Oncology ,Palliative care ,Palliative radiotherapy ,Symptom management ,Aggressiveness of care - Abstract
Background On the basis of substantial evidence demonstrate that palliative care combined with standard care improves patient, caregiver, and society outcomes, we have developed a new healthcare model called radiotherapy and palliative care (RaP) outpatient clinic were a radiation oncologist and a palliative care physician make a joint evaluation of advanced cancer patients. Methods We performed a monocentric observational cohort study on advanced cancer patients referred for evaluation at the RaP outpatient clinic. Measures of quality of care were carried out. Results Between April 2016 and April 2018, 287 joint evaluations were performed and 260 patients were evaluated. The primary tumor was lung in 31.9% of cases. One hundred fifty (52.3%) evaluations resulted in an indication for palliative radiotherapy treatment. In 57.6% of cases was used a single dose fraction of radiotherapy (8 Gy). All the irradiated cohort completed the palliative radiotherapy treatment. An 8% of irradiated patients received the palliative radiotherapy treatment in the last 30 days of life. A total of 80% of RaP patients received palliative care assistance until the end of life. Conclusion At the first descriptive analysis, the radiotherapy and palliative care model seem to respond to the need of multidisciplinary approach in order to obtain an improvement on quality of care for advanced cancer patients.
- Published
- 2023
7. 84P Autologous ECM-composed scaffolds and zebrafish PDXs for individualized theranostics in rare neuroendocrine neoplasms
- Author
-
Calabrese, C., primary, Miserocchi, G., additional, Vanni, S., additional, Spadazzi, C., additional, De Vita, A., additional, Cocchi, C., additional, Bongiovanni, A., additional, Ranallo, N., additional, Pieri, F., additional, Frassineti, G.L., additional, Tebaldi, M., additional, Foca, F., additional, Ercolani, G., additional, Cavaliere, D., additional, Pacilio, C.A., additional, Mercatali, L., additional, and Liverani, C., additional
- Published
- 2022
- Full Text
- View/download PDF
8. 48P Phase II trial on vaccination with autologous dendritic cells loaded with autologous tumour homogenate in resected glioblastoma (COMBI-GVAX): Clinical results of the first step
- Author
-
Ridolfi, L., Gurrieri, L., Riva, M.N., Bulgarelli, J., Fausti, V., F. de Rosa, Guidoboni, M., Foca, F., Tazzari, M., Petrini, M., Granato, A.M., Pancisi, E., Dall'Agata, M., Amadori, E., Gamboni, A., Pasini, G., Cortesi, P., Mercatali, L., Bongiovanni, A., and Tosatto, L.
- Published
- 2022
- Full Text
- View/download PDF
9. P992: OUTCOMES OF GLOBAL COAGULATION ASSAYS IN PATIENTS WITH PHILADELPHIA-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS WITH RESPECT TO THEIR CLINICAL AND GENETIC DETERMINANTS OF CLONAL EVOLUTION
- Author
-
Lucchesi, A., primary, Napolitano, R., additional, Bochicchio, M. T., additional, Simonetti, G., additional, Micucci, G., additional, Poggiaspalla, M., additional, Di Battista, V., additional, Musuraca, G., additional, Foca, F., additional, Giordano, G., additional, Catani, L., additional, and Napolitano, M., additional
- Published
- 2022
- Full Text
- View/download PDF
10. C4 - Bone health management in early breast cancer patients: an Italian Osteoncology Center experience
- Author
-
Recine, F., Bongiovanni, A., Fausti, V., Mercatali, L., Riva, N., Calpona, S., Faedi, M., De Vita, A., Liverani, C., Spadazzi, C., Miserocchi, G., Foca, F., Vespignani, R., Rocca, A., Amadori, D., and Ibrahim, T.
- Published
- 2017
- Full Text
- View/download PDF
11. 381TiP Vaccination with autologous dendritic cells loaded with autologous tumour homogenate in resected glioblastoma: A phase II study (CombiGVax)
- Author
-
Ridolfi, L., primary, Gurrieri, L., additional, Riva, N., additional, Fausti, V., additional, Bongiovanni, A., additional, Di Menna, G., additional, de Rosa, F., additional, Guidoboni, M., additional, Mercatali, L., additional, Bulgarelli, J., additional, Foca, F., additional, Tazzari, M., additional, Calpona, S., additional, Petrini, M., additional, Granato, A., additional, Pancisi, E., additional, Dall'Agata, M., additional, Valmorri, L., additional, Tosatto, L., additional, and Ibrahim, T., additional
- Published
- 2021
- Full Text
- View/download PDF
12. 1296P Immune checkpoint inhibitors with or without bone targeted therapy in NSCLC patients with bone metastases and prognostic significance of neutrophil-to-lymphocyte ratio
- Author
-
Bongiovanni, A., primary, Foca, F., additional, Menis, J., additional, Stucci, L.S., additional, Artioli, F., additional, Guadalupi, V., additional, Forcignanò, M.R.C., additional, Fantini, M., additional, Recine, F., additional, Mercatali, L., additional, Spadazzi, C., additional, De Vita, A., additional, Casadei, R., additional, Falasconi, M.C., additional, Fausti, V., additional, Pallotti, M.C., additional, Bertoni, M., additional, Vanni, S., additional, and Ibrahim, T., additional
- Published
- 2021
- Full Text
- View/download PDF
13. 1103P 177Lu-DOTATATE efficacy and safety in functioning neuroendocrine tumors: A joint analysis of phase II prospective clinical trials
- Author
-
Bongiovanni, A., primary, Nicolini, S., additional, Foca, F., additional, Sansovini, M., additional, Grassi, I., additional, Liverani, C., additional, Riva, N., additional, Fausti, V., additional, Mercatali, L., additional, De Vita, A., additional, Fabbri, L., additional, Signoretti, M., additional, Pacilio, C.A., additional, Paganelli, G., additional, Severi, S., additional, Ibrahim, T., additional, and Tartaglia, A., additional
- Published
- 2021
- Full Text
- View/download PDF
14. 1826P Lutetium-177-PSMA in pre- and post-taxane mCRPC setting: Results from a phase II clinical trial
- Author
-
Giunta, E.F., Sansovini, M., Grassi, I., Marini, I., Brighi, N., Lolli, C., Schepisi, G., Nicolini, S., Foca, F., Monti, M., Celli, M., Caroli, P., Di Iorio, V., Sarnelli, A., Severi, S., Paganelli, G., Matteucci, F., and De Giorgi, U.F.F.
- Published
- 2023
- Full Text
- View/download PDF
15. 525P Immuno markers in newly glioblastoma patients underwent Stupp protocol after neurosurgery
- Author
-
Gurrieri, L., Mercatali, L., Ibrahim, T., Fausti, V., Dall'Agata, M., Riva, M.N., Ranallo, N., Pasini, G., Tazzari, M., Foca, F., Bartolini, D., Riccioni, L., Cavatorta, C., Morigi, F., Bulgarelli, J., Cocchi, C., Ghini, V., Tosatto, L., and Ridolfi, L.
- Published
- 2023
- Full Text
- View/download PDF
16. UP43 - Therapy with 177Lu-PSMA-617 in advanced mCRPC patients: Results of the phase 2 prospective trial IRST-185.03 (EUDRACT: 2016-002732-32)
- Author
-
Marini, I., Sansovini, M., Paganelli, G., Grassi, I., Matteucci, F., Nicolini, S., De Giorgi, U., Giunta, E.F., Foca, F., Monti, M., Celli, M., Caroli, P., Di Iorio, V., Sarnelli, A., Lolli, C., Schepisi, G., Brighi, N., and Severi, S.
- Published
- 2023
- Full Text
- View/download PDF
17. GOSAFE - Geriatric Oncology Surgical Assessment and Functional rEcovery after Surgery: early analysis on 977 patients
- Author
-
Montroni, I, Rostoft, S, Spinelli, A, Van Leeuwen, BL, Ercolani, G, Saur, NM, Jaklitsch, MT, Somasundar, PS, Carino, ND, Ghignone, F, Foca, F, Zingaretti, C, Audisio, RA, Ugolini, G, Garutti, A, Taffurelli, G, Zattoni, D, Tramelli, P, Sermonesi, G, Di Candido, F, Carvello, M, Sacchi, M, De Lucia, F, Foppa, C, Plas, M, Van der Wal-Huisman, H, Tauceri, F, Perenze, B, Di Pietrantonio, D, Mirarchi, M, Fejka, M, Bleier, JIS, Frain, L, Fox, SW, Cardin, K, De Leon, LE, Baltatzis, M, Chan, AKC, Siriwardena, AK, Vertogen, B, Nanni, O, Garulli, G, Alagna, V, Pirrera, B, Lucchi, A, Monari, F, Conti, L, Capelli, P, Romboli, A, Palmieri, G, Banchini, F, Marano, L, Spaziani, A, Castagnoli, G, Bartoli, A, Trompetto, M, Gallo, G, Luc, AR, Clerico, G, Sammarco, G, De Luca, R, Barile, G, Simone, M, Costanzi, A, Mari, G, Maggioni, D, Pellegrino, R, Riggio, V, Kenig, J, Szabat, K, Scabini, S, Pertile, D, Stratta, E, Massobrio, A, Soriero, D, Nesbakken, A, Lonn, M, Backe, IF, Ferrari, G, Mazzola, M, Alampi, BDA, Achilli, P, Sfondrini, S, Ioannidis, O, Loutzidou, L, Galanos-Demiris, K, Pellino, G, Balducci, G, Frezza, B, Lucarini, A, Santos, C, Cooper, L, Siam, B, Levy, Y, Brenner, B, Kashtan, H, Belgrano, V, De Cian, F, Palermo, B, Eggenhoffner, R, Albertelli, M, Sanchez-Guillen, L, Arroyo, A, Lopez-Rodriguez, F, Lario, S, Lillo, C, Wexner, SD, SIOG Surgical Task Force, and ESSO GOSAFE Study Grp
- Subjects
MULTICENTER ,CANCER - Abstract
Objective: Older patients with cancer value functional outcomes as much as survival, but surgical studies lack functional recovery (FR) data. The value of a standardized frailty assessment has been confirmed, yet it's infrequently utilized due to time restrictions into everyday practice. The multicenter GOSAFE study was designed to (1) evaluate the trajectory of patients' quality of life (QoL) after cancer surgery (2) assess baseline frailty indicators in unselected patients (3) clarify the most relevant tools in predicting FR and clinical outcomes. This is a report of the study design and baseline patient evaluations. Materials & Methods: GOSAFE prospectively collected a baseline multidimensional evaluation before major elective surgery in patients (70 years) from 26 international units. Short-/mid-/Iong-term surgical outcomes were recorded with QoL and FR data. Results: 1003 patients were enrolled in a 26-month span. Complete baseline data were available for 977(97.4%). Median age was 78 years (range 70-94); 52.8% males. 968(99%) lived at home, 51.6% without caregiver. 54.4% had 3 medications, 5.9% none. Patients were dependent (ADL < 5) in 7.9% of the cases. Frailty was either detected by G8 = 2(37.4%), TUG > 20 s (5.2%) or ASAIII-IV (48.8%). Major comorbidities (CACI > 6) were detected in 36%; 20.9% of patients had cognitive impairment according to Mini-Cog. Conclusion: The GOSAFE showed that frailty is frequent in older patients undergoing cancer surgery. QoL and FR, for the first time, are going to be primary outcomes of a real-life observational study. The crucial role of frailty assessment is going to be addressed in the ability to predict postoperative outcomes and to correlate with QoL and FR. (C) 2019 Elsevier Ltd. All rights reserved.
- Published
- 2020
18. A New Integrated Healthcare Model: Radiotherapy and Palliative Care (RaP) Outpatient Clinic
- Author
-
Rossi, R., primary, FOCA, F., additional, Tontini, L., additional, Micheletti, S., additional, Romeo, A., additional, Altini, M., additional, Nanni, O., additional, and Maltoni, M., additional
- Published
- 2020
- Full Text
- View/download PDF
19. 1175P Temozolomide alone or combined with capecitabine for the treatment of metastatic neuroendocrine neoplasia: A “Real World” data analysis
- Author
-
Bongiovanni, A., primary, Liverani, C., additional, Foca, F., additional, Signoretti, M., additional, Pieri, F., additional, Tartaglia, A., additional, Galassi, R., additional, Cavaliere, D., additional, Severi, S., additional, Fausti, V., additional, Di Menna, G., additional, Mercatali, L., additional, De Vita, A., additional, Riva, N., additional, Calpona, S., additional, Miserocchi, G., additional, Spadazzi, C., additional, and Ibrahim, T., additional
- Published
- 2020
- Full Text
- View/download PDF
20. 1170P The prognostic role of DLL3 expression in high-grade gastroenteropancreatic neuroendocrine neoplasms
- Author
-
Liverani, C., primary, Bongiovanni, A., additional, Mercatali, L., additional, Pieri, F., additional, Spadazzi, C., additional, Miserocchi, G., additional, Di Menna, G., additional, Foca, F., additional, Ravaioli, S., additional, Aprile, M.R., additional, De vita, A., additional, Cocchi, C., additional, Recine, F., additional, and Ibrahim, T., additional
- Published
- 2020
- Full Text
- View/download PDF
21. 606P Novel miRNA-based assay for GEP-NENs management
- Author
-
Bocchini, M., primary, Mazza, M., additional, Simonetti, G., additional, Tazzari, M., additional, Piccinini, F., additional, Ravaioli, S., additional, Foca, F., additional, Tebaldi, M., additional, Nicolini, F., additional, Grassi, I., additional, Severi, S., additional, and Paganelli, G., additional
- Published
- 2020
- Full Text
- View/download PDF
22. Clinical value of negative 68Ga-PSMA PET/CT in the management of biochemical recurrent prostate cancer patients
- Author
-
Celli, M, primary, De Giorgi, U, additional, Caroli, P, additional, Di Iorio, V, additional, Fantini, L, additional, Rossetti, V, additional, Foca, F, additional, Nicolini, S, additional, Giganti, M, additional, Paganelli, G, additional, and Matteucci, F, additional
- Published
- 2020
- Full Text
- View/download PDF
23. Microbiological evaluation of environmental cleanliness in haematopoietic cell transplant patient rooms: implementing JACIE standards
- Author
-
Zeneli, A., primary, Petrini, M., additional, Foca, F., additional, Bernabini, M., additional, Ronconi, S., additional, Montalti, S., additional, Pancisi, E., additional, Soldati, V., additional, Golinucci, M., additional, Frassineti, G.L., additional, and Altini, M., additional
- Published
- 2020
- Full Text
- View/download PDF
24. miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer
- Author
-
Molinari C, Salvi S, Foca F, Teodorani N, Saragoni L, Puccetti M, Passardi A, Tamberi S, Avanzolini A, Lucci E, and Calistri D
- Subjects
gene copy number ,c-MYC ,neoadjuvant chemo-radiotherapy ,miR-17-92 ,ABCC4 ,rectal cancer ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,lcsh:RC254-282 - Abstract
Chiara Molinari,1 Samanta Salvi,1 Flavia Foca,2 Nazario Teodorani,3 Luca Saragoni,4 Maurizio Puccetti,5 Alessandro Passardi,6 Stefano Tamberi,7 Andrea Avanzolini,8 Enrico Lucci,8 Daniele Calistri1 1Biosciences Laboratory, 2Unit of Biostatistics and Clinical Trials, 3Radiotherapy Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, 4Pathology Unit, Morgagni-Pierantoni Hospital, Forlì, 5Pathology Unit, Santa Maria delle Croci Hospital, Ravenna, 6Department of Medical Oncology, IRST IRCCS, Meldola, 7Department of Medical Oncology, Infermi Hospital, Faenza, 8Department of General Surgery, Morgagni-Pierantoni Hospital, Forlì,Italy Abstract: Neoadjuvant chemoradiotherapy (NCRT) followed by surgery is the gold standard for the treatment of patients with locally advanced rectal cancer (LARC). However, response is variable, and no predictive markers have been validated. The amplification of 13q31–34 seemed to distinguish between nonresponders and responders to NCRT. The miR-17-92a-1 cluster host gene (MIR17HG), which is involved in the development, progression, and aggressiveness of colorectal cancer, and the ABCC4 gene, an ATP-binding cassette transporter, are located at this region. Moreover, the transcription factor c-Myc is closely related to MIR17HG. The aim of this study was to examine the role of MIR17HG, ABCC4, and CMYC gene copy numbers (CNs) in determining response to NCRT. We analyzed DNA CN of pretherapy biopsies from 108 LARC patients and the expression of microRNA (miR)-17, miR-18a, miR-19a, miR-19b-1, miR-20a, and miR-92a-1 in 34 biopsies. MIR17HG, CMYC, and ABCC4 gene CNs were frequently altered in pretreatment tumors, amplification being the most frequent alteration. With regard to response to therapy, 41% of responders showed MIR17HG deletion, while MIR17HG amplification was observed in 41% of nonresponders. With regard to pathological T stage (ypT), a higher percentage of ypT3–4 than ypT0–2 tumors showed MIR17HG amplification. Finally, a higher, albeit nonsignificant, variability in the expression of MIR17HG cluster members was detected in nonresponders compared to responders. No association was observed between clinical pathological parameters and ABCC4 or CMYC CN. Our data did not highlight a significant association between MIR17HG, CMYC, and ABCC4 gene CNs and response to NCRT in LARC. However, MIR17HG gene amplification would seem to be related to a lack of response. Evaluation of the expression of MIR17HG cluster members is warranted in a larger case series, together with functional studies, to evaluate the potential of this gene as a new predictive marker. Keywords: rectal cancer, neoadjuvant chemoradiotherapy, gene copy number, MIR17HG, ABCC4, CMYC
- Published
- 2016
25. First-line chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma
- Author
-
Bongiovanni A, Riva N, Ricci M, Liverani C, La Manna F, De Vita A, Foca F, Mercatali L, Severi S, Amadori D, and Ibrahim T
- Subjects
gastroenteropancreatic neuroendocrine carcinomas ,platinum-based chemotherapy ,chemotherapy ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,lcsh:RC254-282 - Abstract
Alberto Bongiovanni,1 Nada Riva,1 Marianna Ricci,1 Chiara Liverani,1 Federico La Manna,1 Alessandro De Vita,1 Flavia Foca,2 Laura Mercatali,1 Stefano Severi,3 Dino Amadori,4 Toni Ibrahim1 1Osteoncology and Rare Tumors Center, 2Unit of Biostatistics and Clinical Trials, 3Nuclear Medicine Unit, 4Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, FC, Italy Background and aim: To investigate the efficacy of platinum-based chemotherapy in patients with metastatic gastroenteropancreatic neuroendocrine carcinoma (mGEP-NEC) and define predictive and prognostic factors. Methods: Twenty mGEP-NEC patients were treated with cisplatin or carboplatin/etoposide between April 2010 and October 2014. Both large-cell and small-cell histologies were included. Cisplatin 25 mg/m2 was administered on days 1–3 followed by etoposide 100 mg/m2 on days 1–3 every 21 days. Carboplatin 300 mg/m2 was administered on day 1 followed by etoposide 100 mg/m2 on days 1–3. Results: Of the 19 evaluable patients, 13 obtained a partial response, four showed stable disease, and two progressed. Median overall survival (mOS) was 13.5 months and median progression-free survival (mPFS) was 10.9 months. Gallium-68 positron emission tomography/computerizsed tomography-positive patients had a higher, albeit not significantly, OS than those with negative results (75% vs 34.3% at 18 months; P=0.06). mPFS was 19.3 and 6.3 months (P55%, respectively. mOS was 8.1 months in the latter group but was not reached in the Ki67 ≤55% group (P-value =0.039). Patients with a lower body mass index (BMI) had a better prognosis in terms of both OS and PFS. Patients with BMI≥25 had a mOS of 11.7 months (P=0.0293) and a mPFS of 6.2 months (P=0.0057). Conclusion: Platinum-based chemotherapy showed good efficacy in mGEP-NEC patients. Those with Ki67 ≤55%, positive Gallium-68 positron emission tomography/computerized tomography and BMI
- Published
- 2015
26. OUTCOMES THAT MATTER TO PATIENTS? THE GERIATRIC ONCOLOGY SURGICAL ASSESSMENT AND FUNCTIONAL RECOVERY AFTER SURGERY (GOSAFE) STUDY: SUBGROUP ANALYSIS OF 440 PATIENTS UNDERGOING COLORECTAL CANCER SURGERY
- Author
-
Saur, N.M., primary, Montroni, I., additional, Ugolini, G., additional, Spinelli, A., additional, Rostoft, S., additional, Somasundar, P., additional, Van Leuween, B., additional, De Liguori Carino, N., additional, Ferrari, G., additional, Ghignone, F., additional, Costanzi, A., additional, Sermonesi, G., additional, Di Candido, F., additional, Foca, F., additional, Zingaretti, C., additional, Vertogen, B., additional, and Audisio, R.A., additional
- Published
- 2019
- Full Text
- View/download PDF
27. PATIENT-REPORTED OUTCOMES MEASURES (PROMS) IN GERIATRIC PATIENTS UNDERGOING MAJOR SURGERY FOR SOLID CANCER: 90-DAY PRELIMINARY REPORT ON 643 PATIENTS FROM THE GERIATRIC ONCOLOGY SURGICAL ASSESSMENT AND FUNCTIONAL RECOVERY AFTER SURGERY (GOSAFE) STUDY
- Author
-
Montroni, I., primary, Ugolini, G., additional, Spinelli, A., additional, Jacklitsh, M., additional, Rostoft, S., additional, Van Leuween, B., additional, Ercolani, G., additional, Somasundar, P., additional, De Liguori Carino, N., additional, Saur, N., additional, Ferrari, G., additional, Ghignone, F., additional, Sermonesi, G., additional, Di Candido, F., additional, Zingaretii, C., additional, Foca, F., additional, Vertogen, B., additional, and Audisio, R.A., additional
- Published
- 2019
- Full Text
- View/download PDF
28. PCN80 REAL-WORLD HEALTHCARE COSTS IN PATIENTS WITH METASTATIC NON SMALL CELL LUNG CANCER IN ITALY
- Author
-
Danesi, V., primary, Massa, I., additional, Altini, M., additional, Balzi, W., additional, Gentili, N., additional, Foca, F., additional, Manunta, S., additional, Ejzykowicz, F., additional, and Delmonte, A., additional
- Published
- 2019
- Full Text
- View/download PDF
29. EP1.16-04 Real World Clinical Outcomes for Metastatic Non-Small Cell Lung Cancer (mNSCLC) at IRST Italy
- Author
-
Altini, M., primary, Massa, I., additional, Balzi, W., additional, Gentili, N., additional, Foca, F., additional, Danesi, V., additional, Manunta, S., additional, Ejzykowicz, F., additional, Chandwani, S., additional, Burgio, M., additional, Cravero, P., additional, Verlicchi, A., additional, Bronte, G., additional, Crino, L., additional, and Delmonte, A., additional
- Published
- 2019
- Full Text
- View/download PDF
30. New circulating biomarkers in gastro-entero-pancreatic-neuroendocrine-tumours
- Author
-
Bocchini, M., primary, Mazza, M., additional, Foca, F., additional, Nicolini, F., additional, Calogero, R.A., additional, Severi, S., additional, and Paganelli, G., additional
- Published
- 2019
- Full Text
- View/download PDF
31. Real-world treatment patterns for metastatic non-small cell lung cancer at IRST Italy
- Author
-
Altini, M., primary, Massa, I., additional, Balzi, W., additional, Gentili, N., additional, Foca, F., additional, Danesi, V., additional, Manunta, S., additional, Burgio, M.A., additional, Cravero, P., additional, Ejzykowicz, F., additional, Chandwani, S., additional, and Delmonte, A., additional
- Published
- 2019
- Full Text
- View/download PDF
32. CAPTEM or FOLFIRI as second-line therapy in neuroendocrine carcinomas and exploratory analysis of predictive role of PET imaging and biological markers (SENECA study)
- Author
-
Bongiovanni, A., primary, Pusceddu, S., additional, Leo, S., additional, Di meglio, G., additional, Gelsomino, F., additional, Pucci, F., additional, Berardi, R., additional, Ricci, S., additional, Lolli, I., additional, Bergamo, F., additional, Campana, D., additional, Santini, D., additional, Tamberi, S., additional, Pastorelli, D., additional, Cives, M., additional, Silvestris, N., additional, Russo, A., additional, Buonadonna, A., additional, Foca, F., additional, and Ibrahim, T., additional
- Published
- 2018
- Full Text
- View/download PDF
33. Italian cancer figures, report 2014: Prevalence and cure of cancer in Italy
- Author
-
Adamo, M., Alessi, D., Aletta, P., Amodio, R., Andreone, S., Angelin, T., Anghinoni, E., Annulli, M., Arciprete, C., Artioli, M., Autelitano, M., Baili, P., Balducci, C., Baracco, M., Baracco, S., Battisti, W., Bella, F., Bellatalla, C., Bellini, A., Belluardo, C., Benatti, P., Benedetto, G., Benfatto, L., Bernazza, E., Bianconi, F., Biavati, P., Bidoli, E., Birri, S., Bizzoco, S., Bonelli, L., Bonini, A., Borciani, E., Bordini, M., Bovo, E., Bozzani, F., Braghiroli, B., Brucculeri, M., Brunori, V., Bucalo, G., Bucchi, L., Bugliarello, E., Bulatko, A., Busco, S., Busso, P., Buzzoni, C., Calabrese, A., Calabretta, L., Caldarella, A., Candela, G., Cannone, G., Canu, L., Caparelli, M., Capocaccia, R., Cappelletti, M., Caprara, L., Carboni, D., Carletti, N., Caroli, S., Cascio, M., Cascone, G., Casella, C., Castaing, M., Cavalieri, D., L, Cecconami, L., Celesia, M., Cena, T., Cercato, M., Cesaraccio, R., Chiesa, R., Cirilli, C., Cocchioni, M., Codazzi, T., Cogno, R., Colamartini, A., Colanino, Z., A, Cometti, I., Contiero, P., Contrino, M., Corbinelli, A., Cordaro, C., Corti, M., Costa, A., Costarelli, D., Coviello, V., Crapanzano, G., Cremone, L., Crocetti, E., Cuccaro, F., Curatella, S., Cusimano, R., D Alò, D., Dal, C., Dal, T., Cin, A., Dal, M., Davini, C., Dottori, D., De, M., Angelis, R., Santis, D., De, E., Valiere, E., Dei, T., Demurtas, G., Devigili, E., Felice, D., Di, E., Grazia, L., Gregorio, D., Di, C., Norcia, R., Prima, D., Dinaro, Y., Distefano, R., Doa, N., Domati, F., Fabiano, S., Facchinelli, G., Falcini, F., Falk, M., Fanetti, A., Fattoruso, S., Federico, M., Ferrari, F., Ferrari, L., Ferretti, S., Fidelbo, M., Filipazzi, L., Fiore, A., Fiori, G., Foca, F., Forgiarini, O., Foschi, R., Francisci, S., Frasca, G., Frassoldi, E., Fusco, M., Gada, D., Garrone, E., Gasparotti, C., Gatta, G., Gatti, L., Gaudiano, C., Gennaro, V., Gentilini, M., Gerevini, C., Ghilardi, S., Ghisleni, S., Giacomin, A., Giavazzi, L., Gigli, A., Gilardi, F., Giorgetti, S., Giorgi, R., P, Giubelli, C., Giuliani, O., Giurdanella, M., Gola, G., Goldoni, C., Golizia, M., Greco, A., Guarda, L., Guttadauro, A., Guzzinati, S., Iachetta, F., Iannelli, A., Ieni, A., Intrieri, T., Kaleci, S., Rosa, L., F, Lando, C., Lavecchia, A., Lazzarato, F., Rose, L., Leone, A., Leone, R., Lonati, F., Lucchi, S., Luminari, S., Macci, L., Macerata, V., Madeddu, A., Maffei, S., Maghini, A., Magnani, C., Magnani, G., Magoni, M., Mallone, S., Mameli, G., Mancini, S., Mancuso, P., Mangone, L., Manneschi, G., Mannino, R., Mannino, S., Marani, E., Marchesi, C., Mariani, F., Martorana, C., Marzola, L., Maspero, S., Maule, M., Mazzei, A., Mazzoleni, G., Mazzucco, G., Melcarne, A., Merletti, F., Merlo, E., Michiara, M., Migliari, E., Minerba, S., Minicuzzi, A., Mizzi, M., Monetti, D., Morana, G., Moroni, E., Mosso, M., Muni, A., Mura, F., Natali, M., Negrino, L., Nemcova, L., Nicita, C., Ocello, C., Pala, F., Palumbo, M., Panciroli, E., Panico, M., Pannozzo, F., Pascucci, C., Pasolini, A., Pastore, G., Patriarca, S., Pedroni, M., Perrotta, C., Pesce, P., Petrinelli, A., Petrucci, C., Pezzarossi, A., Pezzuto, L., Piffer, S., Pinon, M., Antonio Pinto, Pintori, N., Pirani, M., Pirino, D., Pironi, V., Ponz, D., Leon, M., Prandi, R., Prazzoli, R., Puleio, M., Puppo, A., Quarta, F., Quattrocchi, M., Ramazzotti, V., Rashid, I., Ravaioli, A., Ravazzolo, B., Ravegnani, M., Reggiani Bonetti, L., Ricci, P., Rinaldi, E., Rizzello, R., Rognoni, M., Rollo, P., Roncaglia, F., Roncucci, L., Rosano, A., Rossi, F., Rossi, G., Rossi, M., Rossi, S., Rossini, S., Rosso, S., Rudisi, G., Ruggeri, M., Russo, A., Russo, M., Sacchettini, C., Sacchetto, L., Sacco, G., Sacerdote, C., Salvatore, S., Salvi, O., Sampietro, G., Santucci, C., Scheibel, M., Sciacca, S., Sciacchitano, C., Sciacchitano, S., Scuderi, T., Sechi, O., Seghini, P., Senatore, G., Serafini, G., Serraino, D., Sgargi, P., Sini, G., Sobrato, I., Soddu, M., Solimene, C., Spano, F., Spata, E., Sperduti, I., Spinosa, S., Staiti, R., Stocco, C., Stracci, F., Sunseri, R., Sutera, S., Tagliabue, G., Tamburo, L., Tamburrino, S., Taranto, V., Terracini, B., Tisano, F., Tittarelli, A., Tognazzo, S., Torrisi, A., Traina, A., Trama, A., Trapani, C., Tschugguel, B., Tumino, R., Usala, M., Vacirca, S., Valerio, O., Valla, K., Varvarà, M., Vasquez, E., Vassante, B., Vattiato, R., Vercelli, M., Vercellino, P., Vicentini, M., Villa, M., Virdone, S., Francesco Vitale, Vitale, M., Vitali, B., Vitali, M., Vitarelli, S., Zanchi, A., Zanetti, R., Zani, G., Zanier, L., Zappa, M., Zarcone, M., Zevola, A., Zorzi, M., Zucchetto, A., Zucchi, A., Adamo, MS, Alessi, D, Aletta, P, Amodio, R, Andreone, S, Angelin, T, Anghinoni, E, Annulli, ML, Arciprete, C, Artioli, ME, Autelitano, M, Baili, P, Balducci, C, Baracco, M, Baracco, S, Battisti, W, Bella, F, Bellatalla, C, Bellini, A, Belluardo, C, Benatti, P, Benedetto, G, Benfatto, L, Bernazza, E, Bianconi, F, Biavati, P, Bidoli, E, Birri, S, Bizzoco, S, Bonelli, L, Bonini, A, Borciani, E, Bordini, M, Bovo, E, Bozzani, F, Braghiroli, B, Brucculeri, MA, Brunori, V, Bucalo, G, Bucchi, L, Bugliarello, E, Bulatko, A, Busco, S, Busso, P, Buzzoni, C, Calabrese, A, Calabretta, L, Caldarella, A, Candela, G, Cannone, G, Canu, L, Caparelli, M, Capocaccia, R, Cappelletti, M, Caprara, L, Carboni, D, Carletti, N, Caroli, S, Cascio, MA, Cascone, G, Casella, C, Castaing, M, Cavalieri, d'Oro, L, Cecconami, L, Celesia, MV, Cena, T, Cercato, MC, Cesaraccio, R, Chiesa, R, Cirilli, C, Cocchioni, M, Codazzi, T, Cogno, R, Colamartini, A, Colanino, Ziino, A, Cometti, I, Contiero, P, Contrino, ML, Corbinelli, A, Cordaro, C, Corti, M, Costa, A, Costarelli, D, Coviello, V, Crapanzano, G, Cremone, L, Crocetti, E, Cuccaro, F, Curatella, S, Cusimano, R, D'Alò, D, Dal, Cappello, T, Dal, Cin, A, Dal, Maso, L, Davini, C, De, Dottori, M, De, Angelis, R, De, Santis, E, De, Valiere, E, Dei, Tos, AP, Demurtas, G, Devigili, E, Di, Felice, E, di, Grazia, L, Di, Gregorio, C, di, Norcia, R, Di, Prima, A, Dinaro, Y, Distefano, R, Doa, N, Domati, F, Fabiano, S, Facchinelli, G, Falcini, F, Falk, M, Fanetti, AC, Fattoruso, S, Federico, M, Ferrari, F, Ferrari, L, Ferretti, S, Fidelbo, M, Filipazzi, L, Fiore, AR, Fiori, G, Foca, F, Forgiarini, O, Foschi, R, Francisci, S, Frasca, G, Frassoldi, E, Fusco, M, Gada, D, Garrone, E, Gasparotti, C, Gatta, G, Gatti, L, Gaudiano, C, Gennaro, V, Gentilini, MA, Gerevini, C, Ghilardi, S, Ghisleni, S, Giacomin, A, Giavazzi, L, Gigli, A, Gilardi, F, Giorgetti, S, Giorgi, Rossi, P, Giubelli, C, Giuliani, O, Giurdanella, MC, Gola, G, Goldoni, CA, Golizia, MG, Greco, A, Guarda, L, Guttadauro, A, Guzzinati, S, Iachetta, F, Iannelli, A, Ieni, A, Intrieri, T, Kaleci, S, La, Rosa, F, Lando, C, Lavecchia, AM, Lazzarato, F, Le, Rose, L, Leone, A, Leone, R, Lonati, F, Lucchi, S, Luminari, S, Macci, L, Macerata, V, Madeddu, A, Maffei, S, Maghini, A, Magnani, C, Magnani, G, Magoni, M, Mallone, S, Mameli, G, Mancini, S, Mancuso, P, Mangone, L, Manneschi, G, Mannino, R, Mannino, S, Marani, E, Marchesi, C, Mariani, F, Martorana, C, Marzola, L, Maspero, S, Maule, M, Mazzei, A, Mazzoleni, G, Mazzucco, G, Melcarne, A, Merletti, F, Merlo, E, Michiara, M, Migliari, E, Minerba, S, Minicuzzi, A, Mizzi, M, Monetti, D, Morana, G, Moroni, E, Mosso, ML, Muni, A, Mura, F, Natali, M, Negrino, L, Nemcova, L, Nicita, C, Ocello, C, Pala, F, Palumbo, M, Panciroli, E, Panico, M, Pannozzo, F, Pascucci, C, Pasolini, A, Pastore, G, Patriarca, S, Pedroni, M, Perrotta, C, Pesce, P, Petrinelli, AM, Petrucci, C, Pezzarossi, A, Pezzuto, L, Piffer, S, Pinon, M, Pinto, A, Pintori, N, Pirani, M, Pirino, D, Pironi, V, Ponz, de, Leon, M, Prandi, R, Prazzoli, R, Puleio, M, Puppo, A, Quarta, F, Quattrocchi, M, Ramazzotti, V, Rashid, I, Ravaioli, A, Ravazzolo, B, Ravegnani, M, Reggiani-Bonetti, L, Ricci, P, Rinaldi, E, Rizzello, R, Rognoni, M, Rollo, PC, Roncaglia, F, Roncucci, L, Rosano, A, Rossi, F, Rossi, G, Rossi, M, Rossi, S, Rossini, S, Rosso, S, Rudisi, G, Ruggeri, MG, Russo, AG, Russo, M, Sacchettini, C, Sacchetto, L, Sacco, G, Sacerdote, C, Salvatore, S, Salvi, O, Sampietro, G, Santucci, C, Scheibel, M, Sciacca, S, Sciacchitano, C, Sciacchitano, S, Scuderi, T, Sechi, O, Seghini, P, Senatore, G, Serafini, G, Serraino, D, Sgargi, P, Sini, GM, Sobrato, I, Soddu, M, Solimene, C, Spano, F, Spata, E, Sperduti, I, Spinosa, S, Staiti, R, Stocco, C, Stracci, F, Sunseri, R, Sutera, Sardo, A, Tagliabue, G, Tamburo, L, Tamburrino, S, Taranto, V, Terracini, B, Tisano, F, Tittarelli, A, Tognazzo, S, Torrisi, A, Traina, A, Trama, A, Trapani, C, Tschugguel, B, Tumino, R, Usala, M, Vacirca, S, Valerio, O, Valla, K, Varvarà, M, Vasquez, E, Vassante, B, Vattiato, R, Vercelli, M, Vercellino, PC, Vicentini, M, Villa, M, Virdone, S, Vitale, F, Vitale, MF, Vitali, B, Vitali, ME, Vitarelli, S, Zanchi, A, Zanetti, R, Zani, G, Zanier, L, Zappa, M, Zarcone, M, Zevola, A, Zorzi, M, Zucchetto, A, and Zucchi, A
- Subjects
Aged, 80 and over ,Male ,Medicine (all) ,Aged ,Female ,Humans ,Italy ,Middle Aged ,Neoplasms ,Prevalence ,Registries ,Survival Rate ,Socio-culturale ,Settore MED/42 - Igiene Generale E Applicata ,80 and over ,cancer prevalence, cancer incidence, cancer in Italy - Abstract
This Report intends to estimate the total number of people still alive in 2010 after cancer diagnosis in Italy, regardless of the time since diagnosis, and to project these estimates to 2015. This study is also aimed to estimate the number of already cured cancer patients, whose mortality rates have become undistinguishable from that of the general population of the same age and sex.The study took advantage of the information from the AIRTUM database, which included 29 Cancer Registries (covering 21 million people, 35% of the Italian population). A total of 1,624,533 cancer cases diagnosed between 1976 and 2009 contributed to the study. For each registry, the observed prevalence was calculated. Prevalence for lengths of time exceeding the maximum duration of the registration and of the complete prevalence were derived by applying an estimated correction factor, the completeness index. This index was estimated by means of statistical regression models using cancer incidence and survival data available in registries with 18 years of observation or more. For 50 types or combinations of neoplasms, complete prevalence was estimated at 1.1.2010 as an absolute number and as a proportion per 100,000 inhabitants by sex, age group, area of residence, and years since diagnosis. Projections of complete prevalence for 1.1.2015 were computed under the assumption of a linear trend of the complete prevalence observed until 2010. Validated mixture cure models were used to estimate: the cure fraction, that is the proportion of patients who, starting from the time of diagnosis, are expected to reach the same mortality rate of the general population; the conditional relative survival (CRS), that is the cumulative probability of surviving some additional years, given that patients already survived a certain number of years; the time to cure, that is the number of years necessary so that conditional survival in the following five years (5-year CRS) exceeds the conventional threshold of 95% (i.e., mortality rates in cancer patients become undistinguishable compared to those of the general population); the proportion of patients already cured, i.e., people alive since a number of years exceeding time to cure.As of 1.1.2010, it was estimated that 2,587,347 people were alive after a cancer diagnosis, corresponding to 4.4% of the Italian population. A relevant geographical heterogeneity emerged, with a prevalence above 5% in northern registries and below 4% in southern areas. Men were 45% of the total (1,154,289) and women 55% (1,433,058). In the population aged 75 years or more, the proportions of prevalent cases were 20% in males and 13% in females, 11% between 60 and 74 years of age in both sexes. Nearly 600,000 Italian women were alive after a breast cancer diagnosis (41% of all women with this neoplasm), followed by women with cancers of the colon rectum (12%), corpus uteri (7%), and thyroid (6%). In men, 26% of prevalent cases (295,624) were patients with prostate cancer, 16% with either bladder or colon rectum cancer. The projections for 1.1.2015 are of three million (3,036,741) people alive after a cancer diagnosis, 4.9% of the Italian population; with a 20% increase for males and 15% for females, compared to 2010. The cure fractions were heterogeneous according to cancer type and age. Estimates obtained as the sum of cure fractions for all cancer types showed that more than 60% of patients diagnosed below the age of 45 years will reach the same mortality rate of the general population. This proportion decreased with increasing age and it was30% for cancer diagnosed after the age of 74 years. It was observed that 60% of all prevalent cases (1,543,531 people or 2.6% of overall Italian population) had been diagnosed5 years earlier (long-term survivors). Time to cure (5-year CRS95%) was reached in10 years by patients with cancers of the stomach, colon rectum, pancreas, corpus and cervix uteri, brain, and Hodgkin lymphoma. Mortality rates similar to the ones reported by the general population were reached after approximately 20 years for breast and prostate cancer patients. Five-year CRS remained95% for25 years after cancer diagnosis in patients with liver and larynx cancers, non-Hodgkin lymphoma, myeloma, and leukaemia. Time to cure was reached by 27% (20% in men and 33% in women) of all people living after a cancer diagnosis, defined as already cured.The study showed a steady increase over time (nearly +3% per year) of prevalent cases in Italy. A quarter of Italian cancer patients alive in 2010 can be considered as already cured. The AIRTUM Report 2014 describes characteristics of cancer patients and former-patients for 50 cancer types or combinations by sex and age. This detailed information promotes the conduction of studies aimed at expanding the current knowledge on the quality of life of these patients during and after the active phase of treatments (prevalence according to health status), on the long-term effects of treatments (in particular for paediatric patients), on the cost profile of cancer patients, and on rare tumours. All these observations have a high potential impact on health planning, clinical practice, and, most of all, patients' perspective.
- Published
- 2014
34. The advantage of women in cancer survival: An analysis of EUROCARE-4 data
- Author
-
Micheli, A., Ciampichini, R., Oberaigner, W., Ciccolallo, L., de Vries, E., Izarzugaza, I., Zambon, P., Gatta, G., De Angelis, R., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hedelin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadie, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Molinie, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellu`, F., Giacomin, A., Ferretti, S., Serraino, D., Dal Maso, L., De Dottori, M., D. e. Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Patriarca, S., Zanetti, R., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gozdz, S., Siudowska, U., Mezyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Zakelj, M., Mateos, A., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sanchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, A., Talback, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Louis van der Heijden, Null, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., Basque Country Cancer Registry, Vitoria-Gasteiz, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), and Public Health
- Subjects
Oncology ,Male ,Pathology ,Cancer Research ,cancer survival - women ,MESH : Age Distribution ,MESH : Aged ,MESH: Risk Assessment ,[ SDV.CAN ] Life Sciences [q-bio]/Cancer ,0302 clinical medicine ,MESH: Aged, 80 and over ,Residence Characteristics ,Neoplasms ,80 and over ,Gender differences ,Sex hormones ,MESH: Neoplasms ,MESH : Female ,MESH: Residence Characteristics ,Young adult ,Age of Onset ,MESH : Risk Assessment ,MESH : Sex Distribution ,MESH: Diagnosis-Related Groups ,MESH: Aged ,Aged, 80 and over ,0303 health sciences ,education.field_of_study ,MESH: Middle Aged ,Relative survival ,Thyroid ,MESH: Sex Distribution ,Middle Aged ,MESH : Adult ,3. Good health ,MESH : Age of Onset ,Europe ,MESH : Diagnosis-Related Groups ,medicine.anatomical_structure ,MESH: Young Adult ,030220 oncology & carcinogenesis ,MESH: Survival Analysis ,MESH : Residence Characteristics ,Female ,EUROCARE ,Adult ,medicine.medical_specialty ,Adolescent ,MESH: Age of Onset ,MESH : Male ,MESH : Sex Factors ,Population ,MESH : Europe ,MESH : Young Adult ,Rectum ,Socio-culturale ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Risk Assessment ,03 medical and health sciences ,Young Adult ,Age Distribution ,Sex Factors ,MESH: Sex Factors ,SDG 3 - Good Health and Well-being ,Internal medicine ,MESH : Adolescent ,medicine ,Humans ,MESH : Middle Aged ,Sex Distribution ,education ,MESH : Aged, 80 and over ,MESH: Age Distribution ,Survival analysis ,Diagnosis-Related Groups ,030304 developmental biology ,Aged ,MESH: Adolescent ,MESH: Humans ,business.industry ,MESH : Humans ,Cancer ,Cancer survival ,Survival Analysis ,MESH: Adult ,medicine.disease ,MESH : Neoplasms ,MESH: Male ,MESH: Europe ,Age of onset ,MESH : Survival Analysis ,business ,MESH: Female - Abstract
We analysed 1.6 million population-based EUROCARE-4 cancer cases (26 cancer sites, excluding sex-specific sites, and breast) from 23 countries to investigate the role of sex in cancer survival according to age at diagnosis, site, and European region. For 15 sites (salivary glands, head and neck, oesophagus, stomach, colon and rectum, pancreas, lung, pleura, bone, melanoma of skin, kidney, brain, thyroid, Hodgkin disease and non-Hodgkin's lymphoma) age- and region-adjusted relative survival was significantly higher in women than men. By multivariable analysis, women had significantly lower relative excess risk (RER) of death for the sites listed above plus multiple myeloma. Women significantly had higher RER of death for biliary tract, bladder and leukaemia. For all cancers combined women had a significant 5% lower RER of death. Age at diagnosis was the main determinant of the women's advantage, which, however, decreased with increasing age, becoming negligible in the elderly, suggesting that sex hormone patterns may have a role in women's superior ability to cope with cancer. (C) 2008 Elsevier Ltd. All rights reserved.
- Published
- 2009
35. Bone health management in early breast cancer patients: an Italian Osteoncology Center experience
- Author
-
Recine, F., primary, Bongiovanni, A., additional, Fausti, V., additional, Mercatali, L., additional, Riva, N., additional, Calpona, S., additional, Faedi, M., additional, De Vita, A., additional, Liverani, C., additional, Spadazzi, C., additional, Miserocchi, G., additional, Foca, F., additional, Vespignani, R., additional, Rocca, A., additional, Amadori, D., additional, and Ibrahim, T., additional
- Published
- 2017
- Full Text
- View/download PDF
36. Metastatic neuroendocrine neoplasia (mNEN) treatments in over 70 years (y) old patients: A retrospective outcome analysis
- Author
-
Bongiovanni, A., primary, Foca, F., additional, Recine, F., additional, Fausti, V., additional, Riva, N., additional, Setola, E., additional, Faedi, M., additional, Ianniello, A., additional, Pieri, F., additional, Galassi, R., additional, Cavaliere, D., additional, Gardini, A., additional, Tartaglia, A., additional, Lunedei, V., additional, Mercatali, L., additional, Amadori, D., additional, and Ibrahim, T., additional
- Published
- 2017
- Full Text
- View/download PDF
37. Ageing and other factors behind recent cancer incidence and mortality trends in Italy
- Author
-
Crocetti, E, Buzzoni, C, Quaglia, A, Vercelli, M, Mazzoleni, G, Falcini, F, Bucchi, L, Foca, F, Mancini, S, Ravaioli, A, Ferretti, S, Paci, E, Serraino, D, Pannozzo, F, Federico, M, Fusco, M, Michiara, M, Tumino, R, Mangone, L, Donato, A, Budroni, M, Contrino, M, Tessandori, R, Zanetti, R, Piffer, S, Rosa, F, Stracci, F, Zambon, P, Guzzinati, S, Traina, A, Carruba, G, Gennaro, V, Giacomin, A, Donato, F, Vitarelli, S, Bisanti, L, Candela, G, Crosignani, P, de Leon, M, Pisani, P, Pascucci, C, Capocaccia, R., LILLINI, ROBERTO, Crocetti, E, Buzzoni, C, Quaglia, A, Lillini, R, Vercelli, M, Mazzoleni, G, Falcini, F, Bucchi, L, Foca, F, Mancini, S, Ravaioli, A, Ferretti, S, Paci, E, Serraino, D, Pannozzo, F, Federico, M, Fusco, M, Michiara, M, Tumino, R, Mangone, L, Donato, A, Budroni, M, Contrino, M, Tessandori, R, Zanetti, R, Piffer, S, Rosa, F, Stracci, F, Zambon, P, Guzzinati, S, Traina, A, Carruba, G, Gennaro, V, Giacomin, A, Donato, F, Vitarelli, S, Bisanti, L, Candela, G, Crosignani, P, de Leon, M, Pisani, P, Pascucci, C, and Capocaccia, R
- Subjects
Gerontology ,Population ageing ,Population ,Socio-culturale ,cancer incidence trends ,cancer mortality trends ,ageing ,medicine ,Trend ,Mortality ,education ,Lung cancer ,Cancer ,education.field_of_study ,business.industry ,Mortality rate ,Incidence (epidemiology) ,Incidence ,medicine.disease ,Annual Percent Change ,Ageing ,Trends ,Oncology ,Geriatrics and Gerontology ,business ,Demography - Abstract
Objective: The aim of this paper is to outline the age effect on cancer trends observed in Italy between 1998 and 2005. Methods: We analysed crude and age-adjusted cancer incidence and mortality trends for 36 sites and both sexes using data from 22 population-based registries of the Italian Network of Cancer Registries (AIRTUM). Some 818,017 incident cancers and 342,444 cancer deaths were analysed. Results: The population aged 65. years and older increased from 19.0% to 20.6% between 1998 and 2005 with a significant effect on the cancer burden. The all-cancer, age-adjusted incidence rate was quite stable over the period (all sites excluding non-melanoma skin cancers: annual percent change (APC) men +. 0.3 CI +. 0.1/+0.5, women +. 0.2 CI - 0.1/+0.4), but population ageing resulted in a growing number of new cases (crude rates: APC men +. 1.3 CI +. 1.0/+1.7, women +. 0.9 CI +. 0.6/+1.2). This effect was not evident for those cancer sites with high incidence rates among young subjects. The all-cancer, age-adjusted mortality rate decreased in both sexes but the crude rate changed in women only. Mortality increased for lung cancer among women (APC +. 1.5; CI +. 0.5/+2.5) and for melanoma among men (APC +. 2.7; CI +. 0.5/+4.8). Conclusions: Recent cancer trends in Italy are quite favourable, showing decreasing mortality rates for most sites (except for lung cancer among women and melanoma among men) and showing overall stable incidence. However, it follows that population ageing will have increased the cancer diagnostic and therapeutic needs and costs. © 2012 Elsevier Ltd.
- Published
- 2012
38. KO1 - PATIENT-REPORTED OUTCOMES MEASURES (PROMS) IN GERIATRIC PATIENTS UNDERGOING MAJOR SURGERY FOR SOLID CANCER: 90-DAY PRELIMINARY REPORT ON 643 PATIENTS FROM THE GERIATRIC ONCOLOGY SURGICAL ASSESSMENT AND FUNCTIONAL RECOVERY AFTER SURGERY (GOSAFE) STUDY
- Author
-
Montroni, I., Ugolini, G., Spinelli, A., Jacklitsh, M., Rostoft, S., Van Leuween, B., Ercolani, G., Somasundar, P., De Liguori Carino, N., Saur, N., Ferrari, G., Ghignone, F., Sermonesi, G., Di Candido, F., Zingaretii, C., Foca, F., Vertogen, B., and Audisio, R.A.
- Published
- 2019
- Full Text
- View/download PDF
39. O01 - OUTCOMES THAT MATTER TO PATIENTS? THE GERIATRIC ONCOLOGY SURGICAL ASSESSMENT AND FUNCTIONAL RECOVERY AFTER SURGERY (GOSAFE) STUDY: SUBGROUP ANALYSIS OF 440 PATIENTS UNDERGOING COLORECTAL CANCER SURGERY
- Author
-
Saur, N.M., Montroni, I., Ugolini, G., Spinelli, A., Rostoft, S., Somasundar, P., Van Leuween, B., De Liguori Carino, N., Ferrari, G., Ghignone, F., Costanzi, A., Sermonesi, G., Di Candido, F., Foca, F., Zingaretti, C., Vertogen, B., and Audisio, R.A.
- Published
- 2019
- Full Text
- View/download PDF
40. 1385PD - New circulating biomarkers in gastro-entero-pancreatic-neuroendocrine-tumours
- Author
-
Bocchini, M., Mazza, M., Foca, F., Nicolini, F., Calogero, R.A., Severi, S., and Paganelli, G.
- Published
- 2019
- Full Text
- View/download PDF
41. Phase II randomised clinical study of metformin plus chemotherapy vs chemotherapy alone in HER2 negative metastatic breast cancer: final results of the MYME trial
- Author
-
Gennari, A., primary, Nanni, O., additional, Rocca, A., additional, De Censi, A., additional, Fieschi, A., additional, Bologna, A., additional, Gianni, L., additional, Rosetti, F., additional, Amaducci, L., additional, Cavanna, L., additional, Foca, F., additional, Sarti, S., additional, Serra, P., additional, Valmorri, L., additional, Corradengo, D., additional, Antonucci, G., additional, Bruzzi, P., additional, and Amadori, D., additional
- Published
- 2016
- Full Text
- View/download PDF
42. Retrospective analysis of the efficacy of somatostatin analogs (SSA) in metastatic pulmonary neuroendocrine tumors and prognostic significance of FDG-PET
- Author
-
Bongiovanni, A., primary, Recine, F., additional, Marcantognini, G., additional, Riva, N., additional, Fausti, V., additional, Liverani, C., additional, de vita, A., additional, Mercatali, L., additional, Foca, F., additional, Sansovini, M., additional, Pieri, F., additional, Oboldi, D., additional, Galassi, R., additional, Cavaliere, D., additional, Zaccaroni, A., additional, Tartaglia, A., additional, Lunedei, V., additional, Gardini, A., additional, Amadori, D., additional, and Ibrahim, T., additional
- Published
- 2016
- Full Text
- View/download PDF
43. Recombinant granulocyte colony-stimulating factors (rG-CSFs) in the management of NEUtropenia induced by anthracyclines and ifosfamide in patients with soft tissue SARcomas (NEUSAR)
- Author
-
Bongiovanni, A., primary, Monti, M., additional, Foca, F., additional, Recine, F., additional, Riva, N., additional, Di Iorio, V., additional, Liverani, C., additional, Alessandro, D.V., additional, Miserocchi, G., additional, Mercatali, L., additional, Marcantognini, G., additional, Fausti, V., additional, Calpona, S., additional, Amadori, D., additional, and Ibrahim, T., additional
- Published
- 2016
- Full Text
- View/download PDF
44. 1333TiP - CAPTEM or FOLFIRI as second-line therapy in neuroendocrine carcinomas and exploratory analysis of predictive role of PET imaging and biological markers (SENECA study)
- Author
-
Bongiovanni, A., Pusceddu, S., Leo, S., Di meglio, G., Gelsomino, F., Pucci, F., Berardi, R., Ricci, S., Lolli, I., Bergamo, F., Campana, D., Santini, D., Tamberi, S., Pastorelli, D., Cives, M., Silvestris, N., Russo, A., Buonadonna, A., Foca, F., and Ibrahim, T.
- Published
- 2018
- Full Text
- View/download PDF
45. I TUMORI IN ITALIA - RAPPORTO 2013: Tumori multipli = ITALIAN CANCER FIGURES - REPORT 2013: Multiple tumours
- Author
-
Adamo, Ms, Alessi, D, Aletta, P, Amodio, R, Andreone, S, Angelin, T, Anghinoni, E, Annulli, Ml, Antonini, S, Artioli, Me, Autelitano, M, Balducci, C, Balottari, P, Baracco, M, Battisti, W, Bella, F, Bellatalla, C, Belluardo, C, Benatti, P, Benedetto, G, Benfatto, L, Bernazza, E, Bianconi, F, Biavati, P, Bidoli, E, Birri, S, Bizzoco, S, Bonelli, L, Bonini, A, Borciani, E, Bovo, E, Bozzani, F, Bozzeda, A, Braghiroli, B, Brucculeri, Ma, Brunori, V, Bucalo, G, Bucchi, L, Bugliarello, E, Bulatko, A, Busco, S, Busso, P, Buzzoni, C, Calabretta, L, Caldarella, A, Candela, G, Canu, L, Cappelletti, M, Caprara, L, Carboni, D, Carletti, N, Caroli, S, Carone, S, Cascio, Ma, Cascone, G, Casella, C, Castaing, M, Cecconami, L, Celesia, Mv, Cena, T, Cercato, Mc, Cesaraccio, R, Chiesa, R, Cirilli, C, Civaschi, A, Cocchioni, Mario, Codazzi, T, Cogno, R, Colamartini, A, Colanino Ziino, A, Cometti, I, Contiero, P, Contrino, Ml, Corbinelli, A, Cordaro, C, Corti, M, Costa, A, Costarelli, D, Cremone, L, Crocetti, E, Curatella, S, Cusimano, R, D'Alò, D, D'Angelo, S, Dal Cappello, T, Dal Cin, A, Dal Maso, L, Dall'Acqua, M, Dalsasso, F, Davini, C, De Dottori, M, De Maria, V, De Santis, E, De Valiere, E, Dei Tos AP, Demurtas, G, Devigli, E, Di Felice, E, di Grazia, L, Di Gregorio, C, Di Prima, A, Distefano, R, Doa, N, Domati, F, Fabiano, S, Facchinelli, G, Falcini, F, Falk, M, Fanetti, Ac, Fattoruso, S, Federico, M, Ferrari, L, Ferretti, S, Fidelbo, M, Filipazzi, L, Fiore, Ar, Fiori, G, Foca, F, Forgiarini, O, Frasca, G, Frassoldi, E, Frizza, J, Fusco, M, Gada, D, Garrone, E, Gasparotti, C, Gatti, L, Gaudiano, C, Gennaro, V, Gentilini, M, Gerevini, C, Ghilardi, S, Ghisleni, S, Giacomin, A, Giavazzi, L, Gilardi, F, Giorgetti, S, Giubelli, C, Giuliani, O, Giurdanella, Mc, Gola, G, Goldoni, Ca, Golizia, Mg, Grandi, L, Greco, A, Guarda, L, Guttadauro, A, Guzzinati, S, Iachetta, F, Iannelli, A, Ieni, A, Intrieri, T, Kaleci, S, La Rosa, F, Lando, C, Lavecchia, Am, Lazzarato, F, Leone, A, Leone, R, Lonati, F, Lottero, B, Lucchi, S, Luminari, S, Macci, L, Macerata, V, Madeddu, A, Maffei, S, Maghini, A, Magnani, C, Magnani, G, Magoni, M, Mameli, G, Mancini, S, Mancuso, P, Mangone, L, Manneschi, G, Mannino, R, Mannino, S, Marani, E, Mariani, F, Martorana, C, Marzola, L, Maspero, S, Maule, M, Mazzei, A, Mazzoleni, G, Mazzucco, G, Melcarne, A, Merletti, F, Michiara, M, Migliari, E, Minerba, S, Minicuzzi, A, Mizzi, M, Monetti, D, Morana, G, Moroni, E, Mosso, Ml, Muni, A, Mura, F, Natali, M, Nemcova, L, Nicita, C, Ocello, C, Paci, E, Pala, F, Palumbo, M, Panico, M, Pannozzo, F, Pascucci, Cristiana, Pastore, G, Patriarca, S, Pedroni, M, Pellegri, C, Perrotta, C, Pesce, P, Petrinelli, Am, Petrucci, C, Pezzarossi, A, Piffer, S, Pintori, N, Pirani, M, Pirino, D, Pironi, V, Ponz de Leon, M, Prandi, R, Prazzoli, R, Preto, L, Puleio, M, Puppo, A, Quaglia, A, Quarta, F, Quattrocchi, M, Raho, Am, Ramazzotti, V, Rashid, I, Ravaioli, A, Ravazzolo, B, Ravegnani, M, Reggiani Bonetti, L, Ribaudo, M, Rinaldi, E, Ricci, P, Rizzello, R, Rollo, Pc, Roncucci, L, Rosano, A, Rossi, F, Rossi, G, Rossi, M, Rossini, S, Rosso, S, Rudisi, G, Ruggeri, Mg, Russo, Ag, Russo, M, Sacchettini, C, Sacco, G, Sacerdote, C, Salvatore, S, Salvi, O, Sampietro, G, Sandrini, M, Santucci, C, Scheibel, M, Schiacchitano, S, Sciacca, S, Sciacchitano, C, Scuderi, T, Sechi, O, Seghini, P, Senatore, G, Serafini, G, Serraino, D, Sgargi, P, Sigona, A, Sini, Gm, Sobrato, I, Soddu, M, Solimene, C, Spano, F, Spata, E, Sperduti, I, Staiti, R, Stocco, C, Stracci, F, Sunseri, R, Sardo, As, Tagliabue, G, Tamburo, L, Tamburrino, S, Tanzarella, M, Terracini, B, Tessandori, R, Tisano, F, Tittarelli, A, Tognazzo, S, Torrisi, A, Traina, A, Trapani, C, Tschugguel, B, Tumino, R, Usala, M, Vacirca, S, Valerio, O, Valla, K, Varvarà, M, Vasquez, E, Vassante, B, Vattiato, R, Vercelli, M, Vercellino, Pc, Vicentini, M, Villa, M, Vitale, F, Vitale, Mf, Vitali, B, Vitarelli, Susanna, Zanchi, A, Zanetti, R, Zani, G, Zanier, L, Zappa, M, Zarcone, M, Zevola, A, Zucchetto, A, and Zucchi, A.
- Published
- 2013
46. Decreasing incidence of late-stage breast cancer after the introduction of organized mammography screening in Italy
- Author
-
Foca, F, Mancini, S, Bucchi, L, Puliti, D, Zappa, M, Naldoni, C, Falcini, F, Gambino, Ml, Piffer, S, Sanoja Gonzalez ME, Stracci, F, Zorzi, M, Paci, E, IMPACT Working Group, and Ferretti, Stefano
- Subjects
breast cancer, incidence, mammography, screening, tumor stage ,mammography ,screening ,Breast Neoplasms ,Middle Aged ,NO ,breast cancer ,Italy ,incidence ,Humans ,Female ,tumor stage ,Early Detection of Cancer ,Aged ,Randomized Controlled Trials as Topic - Abstract
After the introduction of a mammography screening program, the incidence of late-stage breast cancer is expected to decrease. The objective of the current study was to evaluate variations in the total incidence of breast cancer and in the incidence of breast cancers with a pathologic tumor (pT) classification of pT2 through pT4 after the introduction of mammography screening in 6 Italian administrative regions.The study area included 700 municipalities, with a total population of 692,824 women ages 55 to 74 years, that were targeted by organized mammography screening between 1991 and 2005. The year screening started at the municipal level (year 1) was identified. The years of screening were numbered from 1 to 8. The ratio of the observed 2-year, age-standardized (Europe) incidence rate to the expected rate (the incidence rate ratio [IRR]) was calculated. Expected rates were estimated assuming that the incidence of breast cancer was stable and was equivalent to that in the last 3 years before year 1.The study was based on a total of 14,447 incident breast cancers, including 4036 pT2 through pT4 breast cancers. The total IRR was 1.35 (95% confidence interval, 1.03-1.41) in years 1 and 2, 1.16 (95% confidence interval, 1.10-1.21) in years 3 and 4, 1.14 (95% confidence interval, 1.08-1.20) in years 5 and 6, and 1.14 (95% confidence interval, 1.08-1.21) in years 7 and 8. The IRR for pT2 through pT4 breast cancers was 0.97 (95% confidence interval, 0.90-1.04) in years 1 and 2, 0.81 (95% confidence interval, 0.75-0.88) in years 3 and 4, 0.79 (95% confidence interval, 0.73-0.87) in years 5 and 6, and 0.71 (95% confidence interval, 0.64-0.79) in years 7 and 8.A significant and stable decrease in the incidence of late-stage breast cancer was observed from the third year of screening onward, when the IRR varied between 0.81 and 0.71.
- Published
- 2013
47. Predictions of survival up to 10 years after diagnosis for european women with breast cancer in 2000-2002
- Author
-
Allemani, Claudia, Minicozzi, Pamela, Berrino, Franco, Bastiaannet, Esther, Gavin, Anna, Galceran, Jaume, Ameijide, Alberto, Siesling, Sabine, Mangone, Lucia, Ardanaz, Eva, Hã©delin, Guy, Mateos, Antonio, Micheli, Andrea, Sant, Milena, Holub, J., Jurickova, L., Hakulinen, T., Tryggvadottir, L., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Micheli, A., Margutti, C., Minicozzi, P., Sant, M., Sowe, S., Tereanu, C., Zigon, G., Ferretti, S., Federico, M., Rashid, I., Cirilli, C., De Lisi, V., Bozzani, F., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Falcini, F., Foca, F., Giorgetti, S., Paci, E., Crocetti, E., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mäå¼yk, R., Bielska-Lasota, M., Zwierko, M., Safaei Diba, C., PrimiÄ-Žakelj, M., Klint, Ã. ., Talbã¤ck, M., Usel, M., Ess, S. M., Lutz, J. M., Pury, P., Visser, O., Greenberg, D. C., Coleman, M. P., Woods, L., Forman, D., Cooper, N., Roche, M., Lawrence, G., Black, R. J., Brewster, D. H., and Steward, J. A.
- Subjects
Adult ,medicine.medical_specialty ,Cancer Research ,Adolescent ,Population ,breast cancer ,cancer survival ,Socio-culturale ,Breast Neoplasms ,Disease ,Breast cancer ,Age Distribution ,medicine ,80 and over ,Humans ,Registries ,Stage (cooking) ,education ,Survival rate ,Survival analysis ,EUROCARE ,long-term survival ,stage ,Aged ,Aged, 80 and over ,Europe ,Female ,Middle Aged ,Prognosis ,Survival Analysis ,Survival Rate ,Oncology ,Gynecology ,education.field_of_study ,Relative survival ,business.industry ,Cancer ,medicine.disease ,business ,Demography - Abstract
Few studies have addressed longer-term survival for breast cancer in European women. We have made predictions of 10-year survival for European women diagnosed with breast cancer in 2000-2002. Data for 114,312 adult women (15-99 years) diagnosed with a first primary malignant cancer of the breast during 2000-2002 were collected in the EUROCARE-4 study from 24 population-based cancer registries in 14 European countries. We estimated relative survival at 1, 5, and 10 years after diagnosis for women who were alive at some point during 2000-2002, using the period approach. We also estimated 10-year survival conditional on survival to 1 and 5 years after diagnosis. Ten-year survival exceeded 70% in most regions, but was only 54% in Eastern Europe, with the highest value in Northern Europe (about 75%). Ten-year survival conditional on survival for 1 year was 2-6% higher than 10-year survival in all European regions, and geographic differences were smaller. Ten-year survival for women who survived at least 5 years was 88% overall, with the lowest figure in Eastern Europe (79%) and the highest in the UK (91%). Women aged 50-69 years had higher overall survival than older and younger women (79%). Six cancer registries had adequate information on stage at diagnosis; in these jurisdictions, 10-year survival was 89% for local, 62% for regional and 10% for metastatic disease. Data on stage are not collected routinely or consistently, yet these data are essential for meaningful comparison of population-based survival, which provides vital information for improving breast cancer control. What's new? Policy-makers and health-care planners need accurate data on long-term survival to improve cancer control. This Europe-wide study of 10-year survival identified low survival in Eastern Europe for women with breast cancer in 2000-2002, and wide variation by age at diagnosis. Data on stage at diagnosis are crucial for meaningful comparison of population-based survival, and fundamental for improving breast cancer control, but our analyses confirmed that stage data are not collected routinely or consistently
- Published
- 2013
48. Invasive extramammary Paget's disease and the risk for secondary tumours in Europe
- Author
-
Van Der Zwan, J. M., Siesling, S., Blokx, W. A. M., Pierie, J. P. E. N., Capocaccia, R., Hackl, M., Zielonk, N., Van Eycken, E., Verstreken, M., Geissler, Jan, Znor, A., Magi, M., Hakulinen, T., Hedelin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Colonna, M., Moliniã©, F., Lacour, B., Desandes, E., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Benhamou, E., Holleczek, B., Wartenberg, Markus, Tryggvadottir, L., Comber, H., Deady, S., Bellã¹, F., Giacomin, A., Pascucci, C., Ferretti, S., Serraino, D., Vercelli, M., Quaglia, A., Vitarelli, S., Federico, M., Cirilli, C., Fusco, M., Traina, A., Michiara, M., Bozzani, F., Pastore, G., Tumino, R., Mangone, L., Falcini, F., Foca, F., Senatore, G., Iannelli, A., Budroni, M., Rosso, S., Piffer, S., Franchini, S., Crocetti, E., Caldarella, A., La Rosa, F., Stracci, F., Contiero, P., Tagliabue, G., Zambon, P., Fiore, A., Berrino, F., Casali, P. G., Gatta, G., Licitra, L., Ruzza, M., Sowe, S., Trama, A., De Angelis, R., Mallone, S., Tavilla, A., Dei Tos, A. P., Fleming, J., England, K., Langmark, F., Bray, F., Rachtan, J., Mezyk, R., Zwierko, M., Bielska-Lasota, M., Slowinski, J., Miranda, A., Primic-Žakelj, M., Ondrusova, M., Mateos, A., Izarzugaza, I., Torella-Ramos, A., Zurriaga, O., Marcos-Gragera, R., Sã¡nchez, M. J., Navarro, C., Chirlaque, M. D., Ardanaz, Eva, Moreno, C., Peris-Bonet, R., Galceran, J., Virizuela-Echaburu, J. A., Gonzalez-Campora, R., Martinez-Garcia, C., Melchor, J. M., Klint, Ã. ., Talbã¤ck, M., Adolfsson, Jan, Lambe, M., Mã¶ller, T. R., Ringborg, Ulrik, Jundt, G., Usel, M., Bouchardy, C., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Dehler, S., Probst-Hensch, N. M., Lutz, J. M., Visser, O., Otter, R., Coebergh, J. W. W., Greenberg, D. C., Forman, D., Roche, M., Stiller, C., Verne, J., Meechan, D., Lawrence, G., Coleman, M. P., Gavin, A., Brewster, D. H., Black, R. J., Kunkler, I., Steward, J., and Faculty of Behavioural, Management and Social Sciences
- Subjects
Male ,Epidemiology ,Paget Disease ,Disease ,Extramammary Paget's ,Neoplasms ,80 and over ,Medicine ,Aged, 80 and over ,Europe ,Rare tumours ,Second cancer risk ,Adult ,Aged ,Female ,Humans ,Incidence ,Middle Aged ,Neoplasm Invasiveness ,Neoplasms, Second Primary ,Paget Disease, Extramammary ,Prognosis ,Risk ,Survival Rate ,Surgery ,Oncology ,IR-81781 ,METIS-284549 ,Relative survival ,Incidence (epidemiology) ,General Medicine ,Second primary cancer ,Second Primary ,Standardized rate ,medicine.medical_specialty ,Socio-culturale ,Extramammary Paget's disease ,Translational research [ONCOL 3] ,Survival rate ,Invasive extramammary Paget's disease ,business.industry ,medicine.disease ,Dermatology ,Extramammary ,risk for secondary tumours ,business - Abstract
Item does not contain fulltext The aim of this study was to determine the incidence and survival of Extramammary Paget's disease (EMPD) and to describe the possible increased risk of tumours after EMPD. All invasive cases diagnosed between 1990 and 2002 were selected from the RARECARE database. Incidence was expressed in European standardized rates. Relative survival was calculated for the period 1995-1999, with a follow-up until 31st December 2003. Standardized incidence ratios of second primary tumours were calculated to reveal possible increased risk after EMPD. European age standardized Incidence of EMPD within Europe is 0.6 per 1000,000 person years. Five-year relative survival for invasive EMPD was 91.2% (95%CI; 83.5-95.4), 8.6 percent of the EMPD patients developed other malignancies. The highest increased risk of developing a second primary tumour was found in the first year of follow-up (SIR:2.0 95%CI; 1.3-2.9), living in the South European region (SIR:2.3 95%CI; 1.5-3.5) or being female (SIR:1.5 95%CI; 1.1-1.9). Female genital organs displayed greatest increased risk of developing a second primary tumour after EMPD (SIR:15,1 95%CI; 0.38-84.23). Due to the increased risk of a second primary tumour after EMPD a thorough search for other tumours during their follow-up is recommended. 01 maart 2012
- Published
- 2012
49. Oesophageal cancer survival in Europe: A EUROCARE-4 study
- Author
-
Gavin, A. T., Francisci, S., Foschi, R., Donnelly, D. W., Lemmens, V., Brenner, H., Anderson, L. A., Oberaigner, W., Hackl, M., Van Eycken, E., Henau, K., Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Casella, I., Margutti, C., Ciccolallo, L., Gatta, G., Micheli, A., Minicozzi, P., Sant, M., Sowe, S., Tereanu, C., Zigon, G., Tagliabue, G., Contiero, P., Bellu`, F., Giacomin, A., Ferretti, S., Serraino, D., Dal Maso, L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Vitarelli, S., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., England, K., Micallef, R., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Go´ z´dz´, S., Siudowska, U., Me?z? yk, R., Bielska-Lasota, M., Sklodowska, M., Zwierko, M., Miranda, A., Diba, C. S., Plesko, I., Primic-Z?akelj, M., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, O., Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Saâ´nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, A., Talbaâck, M., Khan, S., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Konzelmann, I., Dehler, S., Lutz, J. M., Pury, P., Siesling, S., Visser, O., Otter, R., Coebergh, J. W. W., Janssen-Heijnen, M. L., Louis van der Heijden, Null, Greenberg, D. C., Coleman, M. P., Woods, L., Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Black, R. J., Brewster, D. H., Steward, J. A., Bouchardy Magnin, Christine, and Usel, Massimo
- Subjects
Stage ,Adult ,Male ,Cancer Research ,Survival ,Adolescent ,Esophageal Neoplasms ,Epidemiology ,Socio-culturale ,Subtype ,Disease ,Europe/epidemiology ,Young Adult ,Cancer ,Europe ,Oesophagus ,Trends ,Aged ,Aged, 80 and over ,Female ,Humans ,Middle Aged ,Neoplasm Staging ,Prognosis ,Registries ,Survival Rate ,Oncology ,medicine ,80 and over ,Young adult ,Stage (cooking) ,cancer survival ,Survival rate ,ddc:613 ,Relative survival ,business.industry ,Oesophageal cancer ,Cancer survival ,medicine.disease ,Esophageal Neoplasms/mortality/pathology ,business ,Demography ,Cohort study - Abstract
Oesophageal cancer survival is poor with variation across Europe. No pan-European studies of survival differences by oesophageal cancer subtype exist. This study investigates rates and trends in oesophageal cancer survival across Europe. Data for primary malignant oesophageal cancer diagnosed in 1995-1999 and followed up to the end of 2003 was obtained from 66 cancer registries in 24 European countries. Relative survival was calculated using the Hakulinen approach. Staging data were available from 19 registries. Survival by region, gender, age, morphology and stage was investigated. Cohort analysis and the period approach were applied to investigate survival trends from 1988 to 2002 for 31 registries in 17 countries. In total 51,499 cases of oesophageal cancer diagnosed 1995-1999 were analysed. Overall, European 1- and 5-year survival rates were 33.4% (95% CI 32.9-33.9%) and 9.8% (95% CI 9.4-10.1%), respectively. Males, older patients and patients with late stage disease had poorer 1- and 5-year relative survival. Patients with squamous cell carcinoma had poorer 1-year relative survival. Regional variation in survival was observed with Central Europe above and Eastern Europe below the European pool. Survival for distant stage disease was similar across Europe while survival rates for localised disease were below the European pool in Eastern and Southern Europe. Improvement in European 1-year relative survival was reported (p=0.016). Oesophageal cancer survival was poor across Europe. Persistent regional variations in 1-year survival point to a need for a high resolution study of diagnostic and treatment practices of oesophageal cancer.
- Published
- 2012
50. Survival of European patients with central nervous system tumors
- Author
-
Sant, Milena, Minicozzi, Pamela, Lagorio, Susanna, Børge Johannesen, Tom, Marcos-Gragera, Rafael, Francisci, Silvia, Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Guizard, A. V., Danzon, A., Buemi, A., Tretarre, B., Colonna, M., Bara, S., Ganry, O., Grosclaude, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Margutti, C., Micheli, A., Minicozzi, P., Sant, M., Sowe, S., Tereanu, C., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Serraino, D., Dal Maso, L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., De Lisi, V., Bozzani, F., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mezyk, R., Bielska-Lasota, M., Zwierko, M., Miranda, A., Safaei Diba, Chakameh, Primic-Źakelj, M., Izarzugaza, I., Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. ., Talbã¤ck, M., Jundt, G., Usel, M., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Lutz, J. M., Pury, P., Visser, O., Otter, R., Siesling, S., van der Zwan, J. M., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., van der Heijden, Louis, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., and Usel, Massimo
- Subjects
Oncology ,Ependymoma ,Adult ,Male ,medicine.medical_specialty ,Pathology ,Cancer Research ,Adolescent ,Central Nervous System Neoplasms/mortality ,Population ,survival ,NO ,Benign tumor ,Central Nervous System Neoplasms ,Young Adult ,Sex Factors ,Internal medicine ,morphology ,medicine ,80 and over ,Humans ,Registries ,Young adult ,central nervous system tumors ,Europe ,Age Factors ,Aged ,Aged, 80 and over ,Female ,Middle Aged ,Survival Rate ,education ,Survival rate ,ddc:613 ,Medulloblastoma ,education.field_of_study ,Relative survival ,business.industry ,Cancer survival ,Cancer ,central nervous system tumors, survival, morphology, Europe ,medicine.disease ,business - Abstract
We present estimates of population-based 5-year relative survival for adult Europeans diagnosed with central nervous system tumors, by morphology (14 categories based on cell lineage and malignancy grade), sex, age at diagnosis and region (UK and Ireland, Northern, Central, Eastern and Southern Europe) for the most recent period with available data (2000-2002). Sources were 39 EUROCARE cancer registries with continuous data from 1996 to 2002. Survival time trends (1988 to 2002) were estimated from 24 cancer registries with continuous data from 1988. Overall 5-year relative survival was 85.0% for benign, 19.9% for malignant tumors. Benign tumor survival ranged from 90.6% (Northern Europe) to 77.4% (UK and Ireland); for malignant tumors the range was 25.1% (Northern Europe) to 15.6% (UK and Ireland). Survival decreased with age at diagnosis and was slightly better for women (malignant tumors only). For glial tumors, survival varied from 83.5% (ependymoma and choroid plexus) to 2.7% (glioblastoma); and for non-glioma tumors from 96.5% (neurinoma) to 44.9% (primitive neuroectoderm tumor/medulloblastoma). Survival differences between regions narrowed after adjustment for morphology and age, and were mainly attributable to differences in morphology mix; however UK and Ireland and Eastern Europe patients still had 40% and 30% higher excess risk of death, respectively, than Northern Europe patients (reference). Survival for benign tumors increased from 69.3% (1988-1990) to 77.1% (2000-2002); but survival for malignant tumors did not improve indicating no useful advances in treatment over the 14-year study period, notwithstanding major improvement in the diagnosis and treatment of other solid cancers.
- Published
- 2011
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.